MX2019013974A - Complejos de agentes terapéuticos basados en virus y poli(beta-amino éster)es modificados. - Google Patents

Complejos de agentes terapéuticos basados en virus y poli(beta-amino éster)es modificados.

Info

Publication number
MX2019013974A
MX2019013974A MX2019013974A MX2019013974A MX2019013974A MX 2019013974 A MX2019013974 A MX 2019013974A MX 2019013974 A MX2019013974 A MX 2019013974A MX 2019013974 A MX2019013974 A MX 2019013974A MX 2019013974 A MX2019013974 A MX 2019013974A
Authority
MX
Mexico
Prior art keywords
complexes
beta
therapeutic agents
viral
amino ester
Prior art date
Application number
MX2019013974A
Other languages
English (en)
Inventor
Gomez Salvador Borros
Vila Pau Brugada
Cirera Anna Cascante
Fonts Cristina Fillat
Original Assignee
Sagetis Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagetis Biotech Sl filed Critical Sagetis Biotech Sl
Publication of MX2019013974A publication Critical patent/MX2019013974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen complejos de agentes terapéuticos basados en virus con polímeros que son poli(beta-amino éster)es (PBAE) modificados con al menos un oligopéptido. También se describen métodos de tratamiento que usan estos complejos y métodos para encapsular dichos complejos para formar nanopartículas.
MX2019013974A 2017-05-22 2018-05-22 Complejos de agentes terapéuticos basados en virus y poli(beta-amino éster)es modificados. MX2019013974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1708203.3A GB201708203D0 (en) 2017-05-22 2017-05-22 Chemical compounds
PCT/EP2018/063415 WO2018215488A1 (en) 2017-05-22 2018-05-22 Complexes of viral-based therapeutic agents and modified poly(beta-amino ester)s

Publications (1)

Publication Number Publication Date
MX2019013974A true MX2019013974A (es) 2020-08-03

Family

ID=59220679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013974A MX2019013974A (es) 2017-05-22 2018-05-22 Complejos de agentes terapéuticos basados en virus y poli(beta-amino éster)es modificados.

Country Status (12)

Country Link
US (1) US20200147237A1 (es)
EP (1) EP3406265B1 (es)
JP (1) JP7202314B2 (es)
KR (1) KR20200054137A (es)
CN (1) CN110944673B (es)
AU (1) AU2018274622A1 (es)
BR (1) BR112019024581A2 (es)
CA (1) CA3064482A1 (es)
ES (1) ES2821796T3 (es)
GB (1) GB201708203D0 (es)
MX (1) MX2019013974A (es)
WO (1) WO2018215488A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014650A2 (pt) * 2018-01-17 2021-02-17 Aratinga Bio Tnp vetores virais encapsulados em polímero para terapia genética
JP2022549290A (ja) * 2019-09-21 2022-11-24 イグザカ フランス オリゴペプチド修飾ポリ（β－アミノエステル）のＤＭＳＯを含まない合成およびナノ粒子送達システムにおけるそれらの使用
EP4058585A1 (en) * 2019-11-15 2022-09-21 Ixaka France Polymer-encapsulated viral vectors for in vivo genetic therapy
WO2022246093A1 (en) * 2021-05-19 2022-11-24 The Brigham And Women's Hospital, Inc. Nucleic acid-conjugated polymeric nanoparticles and methods of use
CA3225817A1 (en) 2021-07-26 2023-02-02 Salvador Borros Gomez Covalently coated adeno-associated virus vector for its use in gene therapy
EP4166594A1 (en) 2021-10-14 2023-04-19 Institut Químic de Sarrià CETS Fundació Privada Zwitterionic functionalized poly(beta-aminoester) polymers and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2005012407A2 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
EA201100915A1 (ru) * 2008-12-11 2012-01-30 Сайоксус Терапьютикс Лимитед Модификация нуклеиновокислотных векторов с помощью полимеров, включающих заряженные четвертичные аминогруппы
CA2932542C (en) * 2012-12-14 2023-06-06 The Regents Of The University Of California Viral vector nanocapsule for targeting gene therapy and its preparation
GB201304245D0 (en) * 2013-03-08 2013-04-24 Inst Quimic De Sarria Chemical compounds

Also Published As

Publication number Publication date
AU2018274622A1 (en) 2020-01-16
BR112019024581A2 (pt) 2020-06-09
EP3406265A1 (en) 2018-11-28
KR20200054137A (ko) 2020-05-19
US20200147237A1 (en) 2020-05-14
CN110944673A (zh) 2020-03-31
JP7202314B2 (ja) 2023-01-11
WO2018215488A1 (en) 2018-11-29
JP2020520967A (ja) 2020-07-16
ES2821796T3 (es) 2021-04-27
EP3406265B1 (en) 2020-07-29
CN110944673B (zh) 2024-04-26
GB201708203D0 (en) 2017-07-05
CA3064482A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2019013974A (es) Complejos de agentes terapéuticos basados en virus y poli(beta-amino éster)es modificados.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
MX2019008196A (es) Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
GB2557123A (en) Modified cells and methods of therapy
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
EA201790913A1 (ru) Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
MX2017015896A (es) Agente anticancerigeno.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
TW201613650A (en) FVIII conjugates